Compare American Superconductor Corporation (AMSC) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Incyte Corporation — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Incyte Corporation trades at $116.99 (market cap $23.32B). The key difference: Incyte Corporation is far larger — about 13.4× American Superconductor Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | INCY | |
|---|---|---|
Market Cap | $1.74B | $23.32B |
Sector | Technology | Health |
52-Week High | $66.68 | $118.52 |
52-Week Low | $25.95 | $67.38 |
Enterprise Value | $1.61B | $19.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
INCY trades at $116.71, down 1.53% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust revenue of $5.14 billion in 2025, with a net income margin of 26.71%, and recent news highlights regulatory approvals and portfolio expansion, including the acquisition of Vega Therapeutics.
The outlook is positive, driven by earnings beats, product pipeline advancements, and analyst consensus leaning buy. Key risks include execution of recent acquisitions and reliance on key products like Opzelura, but institutional sentiment remains strong with a consensus price target of $107.88.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
